Clinical Trials · NCT07567001

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Phase
Phase 3
Recruitment status
Recruiting
Sponsor
Novo Nordisk A/S
Enrollment
5,610
Start date
May 2026
Locations
838 sites, 27 countries
Primary endpoint
Time to first occurrence of a composite Heart Failure (HF) endpoint consisting of cardiovascular (CV) death
View Amycretin compound reference